Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 165

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Review article: anti‐adhesion therapies for inflammatory bowel disease

Open access
Lobatón, T., Vermeire, S., Van Assche, G., Rutgeerts, P. · 2014 · Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: A high proportion of patients with inflammatory bowel disease (IBD) do not achieve clinical remission with the current therapies including mesalazine (mesalamine), immunossupresants (IMS) and antibodies against tumour necrosis factor (anti‐TNF). Moreover, IMS and anti‐TNF involve a nonnegligible risk for infections and/or malignancies. The anti‐adhesion molecules are one of the most interesting new treatments because of their gut‐selectivity. Aim: To review the physiopathology of the adhesion molecules and the current drugs targeting this mechanism. Methods: We performed a literature review in PubMed and in clinicaltrials.gov using the terms ‘anti‐adhesion molecules’, ‘inflammatory bowel disease’, ‘natalizumab’, ‘vedolizumab’, ‘AMG 181’, ‘Etrolizumab’, ‘PF‐00547659’, ‘AJM 300’, ‘Alicaforsen’ and ‘CCX 282‐B’ up to November 2013. Results: A total of eight drugs were found including those targeting the α4β1, α4β7 or αEβ7 integrins as well as the ICAM‐1 and MA d CAM‐1 addressins and the chemokine receptor 9. The rationale for these drugs is the blockade of gut‐homing T lymphocytes and the ones targeting the α4β7/MA d CAM‐1 interaction presented the most promising results in luminal disease. Vedolizumab, an α4β7 antibody, has completed phase 3 trials with very positive results especially for ulcerative colitis. However, many questions remain unanswered such as the effect of these therapies in perianal disease and extraintestinal manifestations. Conclusions: The blockade of the α4β7/MA d CAM‐1 interaction and especially vedolizumab is an effective and safe gut‐specific treatment for IBD. Further studies are needed to clarify the efficacy and safety of the other anti‐adhesion drugs and to define the specific indications of these therapies in the different scenarios of IBD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.12639

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 165

Metadata

Authors
Lobatón, T., Vermeire, S., Van Assche, G., & Rutgeerts, P.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2014-01-30
Volume
39
Issue
6
Pages
579-594
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2009375421
Cited by
165
References
3
FWCI
17.04
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Review article: anti‐adhesion therapies for inflammatory bowel disease. https://app.cochat.ai/papers/10.1111/apt.12639
The paper
Lobatón, T., Vermeire, S., Van Assche, G., & Rutgeerts, P. (2014). Review article: anti‐adhesion therapies for inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.12639

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.